inHEART
inHEART is a medical technology company specializing in AI-enabled digital twin software for the heart, designed to improve the diagnosis and treatment of cardiac arrhythmias. Their flagship product creates detailed 3D cardiac models from CT and MR images using proprietary segmentation algorithms, enabling personalized, image-guided ablation procedures that reduce procedure times by 60% and recurrence rates by 38%. The solution integrates seamlessly with major electroanatomic mapping systems used during cardiac ablation procedures. inHEART operates on a SaaS business model, serving hospitals and electrophysiology labs globally, with FDA clearance and CE certification under MDR. The company has demonstrated clinical traction with over 1000 cases performed and ongoing randomized controlled trials validating their technology. inHEART is positioned as a leader in precision cardiac care, bridging radiology and cardiology through advanced AI and medical imaging innovation.
inHEART
inHEART is a medical technology company specializing in AI-enabled digital twin software for the heart, designed to improve the diagnosis and treatment of cardiac arrhythmias. Their flagship product creates detailed 3D cardiac models from CT and MR images using proprietary segmentation algorithms, enabling personalized, image-guided ablation procedures that reduce procedure times by 60% and recurrence rates by 38%. The solution integrates seamlessly with major electroanatomic mapping systems used during cardiac ablation procedures. inHEART operates on a SaaS business model, serving hospitals and electrophysiology labs globally, with FDA clearance and CE certification under MDR. The company has demonstrated clinical traction with over 1000 cases performed and ongoing randomized controlled trials validating their technology. inHEART is positioned as a leader in precision cardiac care, bridging radiology and cardiology through advanced AI and medical imaging innovation.
TL;DR
Core product: AI-driven digital twin software that generates patient-specific 3D heart models from CT/MR for planning and guidance of cardiac ablation
Regulatory status: FDA 510(k) clearances and CE certification under MDR
Commercial traction: 1000+ cases performed and ongoing randomized controlled trials
Business model & customers: SaaS serving hospitals and electrophysiology labs
Recent funding: Multiple rounds including $11M (May 2024) and a 750k€ round (Oct 28, 2024)
Company Overview
Problem Domain
Cardiac imaging and interventional electrophysiology—improving planning and guidance for arrhythmia ablation
Founded
2017
Industry
Medical devices / Healthtech
Tech Stack
Funding Track Record
11000000.00
Co-led by Elaia Partners with participation from multiple institutional and crowd investors
750000.00 EUR
Closed Oct 28, 2024 to accelerate imaging platform development
Investor Signal
“Mix of institutional VC (e.g., Vesalius Biocapital IV, Elaia Partners, SWEN Capital) and crowd equity participation”